For the Inventor, By the Inventor

Enter assignee name

La Chaux-de-Fonds, Switzerland

Rhizen Pharmaceuticals Sa

Calculating rank

USPTO Granted Patents = 51

% Expired Patents = 60.8

CIPO Patents = 5

EPO Patents = 20

Forward Citations = 131

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Srikant Viswanadha (36 out of 39 patents)

Meyyappan Muthuppalaniappan (31 out of 32 patents)

Swaroop K Vakkalanka (29 out of 34 patents)

4. Govindarajulu Babu (19 out of 22 patents)

5. Swaroop Kumar V S Vakkalanka (15 out of 15 patents)

6. Prashant Kashinath Bhavar (14 out of 16 patents)

7. Dhanapalan Nagarathnam (14 out of 61 patents)

8. Gayatri Swaroop Merikapudi (13 out of 13 patents)

9. Swaroop K V S Vakkalanka (5 out of 6 patents)

10. Michael S Weiss (2 out of 4 patents)

11. Hari P Miskin (2 out of 3 patents)

12. Peter Sportelli (2 out of 4 patents)

13. Jayaraman Venkat Raman (2 out of 5 patents)

14. Kanthikiran V S Varansi (1 out of 1 patent)

15. Merikapudi Gayatri Swaroop (1 out of 1 patent)

Core Competencies:

PDE4 Inhibitors

PI3K Delta Inhibitors

Kinase Modulators

c-Met Protein Kinases

Calcium Release-Activated Channels

Glutaminase Inhibitors

Anti-CD20 Antibody

Bicyclic Compounds

GPR-119

Immunomodulators

Dual PI3K Inhibitors

Chromen-4-One Compounds

51 patents: Sort by Forward Citations

1. 11066402 - 3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases (2021-07-20),

2. 11065236 - Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor (2021-07-20),

3. 11020399 - Intermediates useful in the synthesis of compounds as modulators of protein kinases (2021-06-01),

4. 10981919 - Selective PI3K delta inhibitors (2021-04-20),

5. 10966977 - Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders (2021-04-06),

6. 10947244 - Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations (2021-03-16),

7. 10851107 - Dual selective P13 delta and gamma kinase inhibitors (2020-12-01),

8. 10786504 - Method of treatment and compositions comprising a dual PI3K delta-gamma kinase inhibitor and a corticosteroid (2020-09-29),

9. 10729768 - Combination of anti-CD20 antibody and PI3 kinase selective inhibitor (2020-08-04),

10. 10668051 - Modulators of calcium release-activated calcium channel (2020-06-02),

11. 10611759 - Glutaminase inhibitors (2020-04-07),

12. 10590129 - 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of protein kinases (2020-03-17),

13. 10570142 - Selective PI3K delta inhibitors (2020-02-25),

14. 10538501 - Kinase modulators (2020-01-21),

15. 10442783 - 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases (2019-10-15),

Company Overview

Rhizen Pharmaceuticals SA, based in La Chaux-de-Fonds, Switzerland, specializes in the development of innovative pharmaceutical compositions targeting various diseases. The company focuses on advanced therapeutic areas, particularly in oncology and immunology, leveraging core technologies such as PDE4 inhibitors, PI3K delta inhibitors, and kinase modulators. Rhizen's research encompasses a range of mechanisms, including c-Met protein kinases and calcium release-activated channels, aiming to address unmet medical needs through novel drug candidates.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

51 Patents

#3 in La Chaux-de-Fonds

#291 in Switzerland

#13,798 in the World

La Chaux-de-Fonds, Switzerland

Rhizen Pharmaceuticals Sa

Forward Citations = 131

17 inventors:

Srikant Viswanadha (36 out of 39 patents)

Meyyappan Muthuppalaniappan (31 out of 32 patents)

Swaroop K Vakkalanka (29 out of 34 patents)

4. Govindarajulu Babu (19 out of 22 patents)

5. Swaroop Kumar V S Vakkalanka (15 out of 15 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Rhizen Pharmaceuticals Sa. Retrieved from https://idiyas.com/company/rhizen-pharmaceuticals-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…